While activation of TAK1 is reported to exacerbate brain damage, pharmacological inhibition of TAK1 using 5Z-7-Oxozeaenol exerts neuroprotection after subarachnoid hemorrhage as well as cerebral ischemia [23, 25, 26]. This evidence concerns the gene MAP3K7 and subarachnoid hemorrhage.